Research Progress in MRNA Drug Modification and Delivery Systems

Overview

Journal Zhejiang Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2023 Aug 29

PMID 37643978

Authors

Zhengjie Zhou

Xin Li

Affiliations

Soon will be listed here.

Abstract

Messenger RNA (mRNA) has shown tremendous potential in disease prevention and therapy. The clinical application requires mRNA with enhanced stability and high translation efficiency, ensuring it not to be degraded by nucleases and targeting to specific tissues and cells. mRNA immunogenicity can be reduced by nucleotide modification, and translation efficiency can be enhanced by codon optimization. The 5´ capping structure and 3´ poly A increase mRNA stability, and the addition of 5' and 3' non-translational regions regulate mRNA translation initiation and protein production. Nanoparticle delivery system protects mRNA from degradation by ubiquitous nucleases, enhances mRNA concentration in circulation and assists it cytoplasmic entrance for the purpose of treatment and prevention. Here, we review the recent advances of mRNA technology, discuss the methods and principles to enhance mRNA stability and translation efficiency; summarize the requirements involved in designing mRNA delivery systems with the potential for industrial translation and biomedical application. Furthermore, we provide insights into future directions of mRNA therapeutics to meet the needs for personalized precision medicine.

References

Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C . Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872770. DOI: 10.1073/pnas.2116271119. View

Bavli Y, Chen B, Gross G, Hershko A, Turjeman K, Roffler S . Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). J Control Release. 2022; 354:316-322. PMC: 9838877. DOI: 10.1016/j.jconrel.2022.12.039. View

Segel M, Lash B, Song J, Ladha A, Liu C, Jin X . Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science. 2021; 373(6557):882-889. PMC: 8431961. DOI: 10.1126/science.abg6155. View

DeLong R, Reynolds C, Malcolm Y, Schaeffer A, Severs T, Wanekaya A . Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromolecules. Nanotechnol Sci Appl. 2013; 3:53-63. PMC: 3781690. DOI: 10.2147/NSA.S8984. View

Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, Foley P . Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther. 2000; 11(17):2403-13. DOI: 10.1089/104303400750038507. View

Henderson J, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N . Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap Analog by In Vitro Transcription. Curr Protoc. 2021; 1(2):e39. DOI: 10.1002/cpz1.39. View

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

Kurland C . Codon bias and gene expression. FEBS Lett. 1991; 285(2):165-9. DOI: 10.1016/0014-5793(91)80797-7. View

Wasungu L, Hoekstra D . Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release. 2006; 116(2):255-64. DOI: 10.1016/j.jconrel.2006.06.024. View

10.

Hernandez-Garcia C, Finer J . Identification and validation of promoters and cis-acting regulatory elements. Plant Sci. 2014; 217-218:109-19. DOI: 10.1016/j.plantsci.2013.12.007. View

11.

Karlsson J, Rhodes K, Green J, Tzeng S . Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities. Expert Opin Drug Deliv. 2020; 17(10):1395-1410. PMC: 7658038. DOI: 10.1080/17425247.2020.1796628. View

12.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

13.

. Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol. 2020; 15(12):963. PMC: 7692425. DOI: 10.1038/s41565-020-00820-0. View

14.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

15.

Cheng Q, Wei T, Jia Y, Farbiak L, Zhou K, Zhang S . Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I. Adv Mater. 2018; 30(52):e1805308. DOI: 10.1002/adma.201805308. View

16.

Zhu G, Chen X . Aptamer-based targeted therapy. Adv Drug Deliv Rev. 2018; 134:65-78. PMC: 6239901. DOI: 10.1016/j.addr.2018.08.005. View

17.

DAcunto M, Cioni P, Gabellieri E, Presciuttini G . Exploiting gold nanoparticles for diagnosis and cancer treatments. Nanotechnology. 2021; 32(19):192001. DOI: 10.1088/1361-6528/abe1ed. View

18.

Passmore L, Coller J . Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat Rev Mol Cell Biol. 2021; 23(2):93-106. PMC: 7614307. DOI: 10.1038/s41580-021-00417-y. View

19.

Lima S, Chipman L, Nicholson A, Chen Y, Yee B, Yeo G . Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017; 24(12):1057-1063. PMC: 5877826. DOI: 10.1038/nsmb.3499. View

20.

Dykman L, Khlebtsov N . Uptake of engineered gold nanoparticles into mammalian cells. Chem Rev. 2013; 114(2):1258-88. DOI: 10.1021/cr300441a. View